Search Results - "Vivas, C. Santos"

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy by Vidal, J., Bellosillo, B., Santos Vivas, C., García-Alfonso, P., Carrato, A., Cano, M.T., García-Carbonero, R., Élez, E., Losa, F., Massutí, B., Valladares-Ayerbes, M., Viéitez, J.M., Manzano, J.L., Azuara, D., Gallego, J., Pairet, S., Capellá, G., Salazar, R., Tabernero, J., Aranda, E., Montagut, C.

“…Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most…”
Get full text

Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma by Fabregat Franco, C., Nieva Muñoz, M., Pérez Martín, F., Ruffinelli, J., Santos Vivas, C., Sánchez, C., Salazar, R., Teule, A.

Get full text

Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients by Martínez-Villacampa, M., Tavera, S. Besora, Vivas, C. Santos, Izquierdo, C., Bruna, J., Velasco, R.

Get full text

G8 screening tool for treatment decision-making in elderly colorectal cancer patients by Marín, J., Soler, G., Martínez-Villacampa, M., Vázquez, S., Vivas, C. Santos, Margalef, N. Mulet, Teule, A., Salazar, R.

Get full text

A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results by Chiritescu, G., Dumon, K., Mercadé, T. Macarulla, Lang, I., Vivas, C. Santos, Papai, Z., Janssens, J., Hendrickx, K., Pracht, M., Van den Eynde, M., Taïeb, J., Moons, V., Geboes, K., Van Laethem, J., Greil, R., Cervantes, A., Vergauwe, P., Ferrante, M., Vanderstraeten, E., Fridrik, M., Wöll, E., Limón, M., Rivera, F., Sagaert, X., Tejpar, S., Van Cutsem, E.

Get full text

Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy by Vidal, J., Dalmeses, A., Vivas, C. Santos, Garcia-Carbonero, R., García-Alfonso, P., Carrato, A., Elez, E., Ortiz, M., Losa, F., Massutí, B., Valladares-Ayerbes, M., Manzano, J., de Prado, J. Vieitez, Gallego, J., Grávalos, C., Varela, M., Azuara, D., Tabernero, J., Salazar, R., Aranda, E., Bellosillo, B., Montagut, C.

Get full text

494P Early-onset colorectal cancer: 10-year cases documented in a comprehensive cancer centre illustrate the importance of a growing oncological problem by Ruffinelli, J.C.C., Guinó, E., Duenas Cid, N., Navarro, M., Moreno, V., Brunet Vidal, J.M., Salazar, R., Santos Vivas, C.

Get full text

418P Colorectal cancer lung metastases resection and its impact on survival in the oligometastatic setting by Ruffinelli Rodriguez, J.C., Guinó, E., Ruiz Valderrama, A., Ibañez, G., Macia Vidueira, I., Padrones Sanchez, S., Navarro Martin, A., Santos Vivas, C.

Get full text

1115P Beyond classic hereditary neuroendocrine tumors (NET) syndromes by Castillo Manzano, C., Guillén, P., Vidal, J.M. Brunet, Lazaro, C., Ruffinelli, J.C.C., Santos Vivas, C., Torrent, F., Lleuger, R., Garcia-Fructuoso, I., Teule, A.

Get full text

P-246Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients by Martínez-Villacampa, M, Tavera, S Besora, Vivas, C Santos, Izquierdo, C, Bruna, J, Velasco, R

Get full text

P-310Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma by Fabregat Franco, C, Nieva Muñoz, M, Pérez Martín, F, Ruffinelli, J, Santos Vivas, C, Sánchez, C, Salazar, R, Teule, A

Get full text

LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients by Lonardi, S., Pietrantonio, F., Tarazona Llavero, N., Montagut Viladot, C., Sartore Bianchi, A., Zampino, M.G., Elez Fernandez, M.E., Santos Vivas, C., Mandalà, M., Tamberi, S., Sciallero, M.S., Muñoz, S., Lazzari, L., Luraghi, P., Torri, V., Cervantes, A., Bardelli, A., Tabernero, J., Siena, S., Marsoni, S.

Get full text

408P Prediction of survival using the G8 scale frailty scale in a prospective series of elderly patients with colon cancer by Soler Gonzalez, G., Raventos, L., Legido-Diaz, R.M., Martínez, C., Torrent, F., Martinez Villacampa, M., Losa, F., Santos Vivas, C., Ruffinelli Rodriguez, J.C., Teule, A., Gallego, M.R., Manzana, A., Rios, A., Sánchez, S., Piera, A., Boixareu, C., Salazar, R., Saldaña Cañada, J.

Get full text

378P Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study by Vidal Barrull, J., Nieva Munoz, M., Fernandez-Rodriguez, C., García Alfonso, P., Paez, D., Alonso-Orduna, V., Cano Osuna, M.T., Santos Vivas, C., Duran, G., Elez Fernandez, M.E., Manzano Mozo, J.L., Garcia-Carbonero, R., Pineda, E., Sastre Varela, J., Rivera Herrero, F., Bellosillo Paricio, B., Tabernero, J., Aranda Aguilar, E., Salazar, R., Montagut Viladot, C.

Get full text

P-248G8 screening tool for treatment decision-making in elderly colorectal cancer patients by Marín, J, Soler, G, Martínez-Villacampa, M, Vázquez, S, Vivas, C Santos, Margalef, N Mulet, Teule, A, Salazar, R

Get full text

P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study by Santos Vivas, C., Salva, F., Fernández-Rodríguez, C., Alonso Orduña, V., Losa, F., Paez, D., Vidal, J., Salud, A., Ribera Fernández, P., Safont Aguilera, M., Tarazona, N., Hernández-Yagüe, X., Layos Romero, L., Garcia-Carbonero, R., Rivera, F., Álvarez Gallego, R., Bellosillo, B., Montagut, C.

Get full text

RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, Vivancos, A.

Get full text

575P - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer by Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, Vivancos, A.

“…So far, no biomarkers of response to anti-angiogenic drugs are available in colorectal cancer (CRC) treatment. Liquid biopsy technique identifies actionable…”
Get full text

Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study by Barrull, J Vidal, Casadevall, D., Fernandez, M.C., Castro-Henriques, M., García-Alfonso, P., Martin-Cullell, B., Alonso-Orduna, V., Alonso, R M Rodríguez, Benavides, M., Vivas, C Santos, Fernández, E Elez, Garcia-Carbonero, R., Ferreiro, R., Manzano, J.L., Losa, F., Salazar, R., Tabernero, J., Aguilar, E Aranda, Bellosillo, B., Viladot, C Montagut

Get full text

625P - Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study by Barrull, J Vidal, Casadevall, D., Fernandez, M.C., Castro-Henriques, M., García-Alfonso, P., Martin-Cullell, B., Alonso-Orduna, V., Alonso, R M Rodríguez, Benavides, M., Vivas, C Santos, Fernández, E Elez, Garcia-Carbonero, R., Ferreiro, R., Manzano, J.L., Losa, F., Salazar, R., Tabernero, J., Aguilar, E Aranda, Bellosillo, B., Viladot, C Montagut

“…Genotyping of ctDNA characterizes the molecular profile and monitors tumor molecular dynamics, but the clinical applicability of next generation sequencing…”
Get full text